Effective Oct. 1 for five years, the Centers for Medicare & Medicaid Services will pay Average Sales Price plus 8%, rather than ASP plus 6%, for biosimilars whose average sales price does not exceed the price of the reference biological product. The payment increase was included in the Inflation Reduction Act of 2022. For new biosimilars that qualify, the five-year period will begin on the first day of the calendar quarter for which ASP payment for that biosimilar begins under Medicare Part B.

Related News Articles

Headline
The AHA today released a detailed summary of the Centers for Medicare & Medicaid Services’ final rule for the calendar year 2023 home health prospective…
Headline
The Department of Health and Human Services today issued a new proposed rule revising the 2020 final rule that established the 340B Administrative Dispute…
Headline
AHA Executive Vice President Michelle Hood previews the 2023 Rural Health Care Leadership Conference, Feb. 19-22 in San Antonio, designed to help rural health…
Headline
In recognition of National Rural Health Day Nov. 17, this last in a two-part series on rural behavioral health shares how a critical access hospital in Newland…
Headline
To honor today’s annual celebration of rural hospitals and health systems, AHA’s John Supplitt, senior director of rural health services, talks with Roxie…
Headline
In recognition of National Rural Health Day on Nov. 17, 2022, AHA today joined a Twitter chat on rural health literacy hosted by the Rural Health Information…